ArticlePloS one2017
Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations.Applied health economics and health policy · 2022Pooled it
- Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020Pooled it
- In-Hospital Hepatitis C Alarm System: A Strategy to Enhance Linkage to Care for Hepatitis C Virus Infection.Gut and liver · 2026Article
- Correspondence to editorial on "Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study".Clinical and molecular hepatology · 2024Article
- Seroprevalence of Hepatitis C Virus Infection in North Korean Defectors Residing in Korea.Journal of Korean medical science · 2023Article
- Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study.Clinical and molecular hepatology · 2023Article
- Cost-effectiveness of chronic hepatitis C screening and treatment.Clinical and molecular hepatology · 2022Review
- A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.Clinical and molecular hepatology · 2022Article
- Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment.PharmacoEconomics · 2021Article
- Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India.BMJ open · 2021Article
- Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable.Clinical liver disease · 2020Review
- Awareness and Access to Therapy in Hepatitis C Virus Infected Patients, Key Barriers to Eliminate the Virus?Gut and liver · 2020Article
- Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.The lancet. Gastroenterology & hepatology · 2020Review
- Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.BMC infectious diseases · 2019Article
- Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines.American health & drug benefits · 2018Article
- Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis.Public health reviews · 2018Review
- Healthcare value of implementing hepatitis C screening in the adult general population in Spain.PloS one · 2018Article
- Current status of and strategies for hepatitis C control in South Korea.Clinical and molecular hepatology · 2017Review
- Current status of hepatitis C virus infection and countermeasures in South Korea.Epidemiology and health · 2017Review
- Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence.MDM policy & practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThis study aims to investigate the cost-effectiveness of a one-time hepatitis C virus (HCV) screening and treatment program in South Korea where hepatitis B virus (HBV) prevails, in people aged 40-70, compared to current practice (no screening).
methodsA published Markov model was used in conjunction with a screening and treatment decision tree to model patient cohorts, aged 40-49, 50-59 and 60-69 years, distributed across chronic hepatitis C (CHC) and compensated cirrhosis (CC) health states (82.5% and 17.5%, respectively). Based on a published seroepidemiology study, HCV prevalence was estimated at 0.60%, 0.80% and 1.53%, respectively. An estimated 71.7% of the population was screened. Post-diagnosis, 39.4% of patients were treated with a newly available all-oral direct-acting antiviral (DAA) regimen over 5 years. Published rates of sustained virologic response, disease management costs, transition rates and utilities were utilised.
resultsScreening resulted in the identification of 43,635 previously undiagnosed patients across all cohorts. One-time HCV screening and treatment was estimated to be cost-effective across all cohorts; predicted incremental cost-effectiveness ratios ranged from $5,714 to $8,889 per quality-adjusted life year gained. Incremental costs associated with screening, treatment and disease management ranged from $156.47 to $181.85 million USD; lifetime costs-offsets associated with the avoidance of end stage liver disease complications ranged from $51.47 to $57.48 million USD.
conclusionsOne-time HCV screening and treatment in South Korean people aged 40-70 is likely to be highly cost-effective compared to the current practice of no screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.